Why the study?
Does synthetic HDL therapy improve prognosis in patients with sepsis?
Does synthetic HDL therapy improve prognosis in patients with sepsis?
This review highlights the potential of raising circulating HDL levels, such as with synthetic HDL, as a therapeutic strategy for sepsis.
HDL decline in sepsis signals poor prognosis; leaves open whether raising HDL improves human outcomes.
High-density lipoprotein (HDL) is a key component of circulating blood and plays essential roles in regulation of vascular endothelial function and immunity. Clinical data demonstrate that HDL levels drop by 40-70% in septic patients, which is associated with a poor prognosis. Experimental studies using Apolipoprotein A-I (ApoAI) null mice showed that HDL deficient mice are susceptible to septic death, and overexpressing ApoAI in mice to increase HDL levels protects against septic death. These clinical and animal studies support our hypothesis that a decrease in HDL level is a risk factor for sepsis, and raising circulating HDL levels may provide an efficient therapy for sepsis. In this review, we discuss the roles of HDL in sepsis and summarize the efforts of using synthetic HDL as a potential therapy for sepsis.
No takes yet. Share an insight, caveat, or question.
Morin et al. (2015) studied this question.
Synapse has enriched 5 closely related papers on similar clinical questions. Consider them for comparative context: